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Highlights 
 
§ Out of over 10 different PKC isoforms, PKC δ and PKC ε are identified as 
effectors that mediate activation of the MAP-kinase pathway downstream of 
mutant GNAQ in uveal melanoma. 
 
§ The RAS exchange factor RasGRP3 is markedly upregulated in uveal melanoma 
cells and is an essential effector that links oncogenic Gq signaling to MAPK 
signaling by three mechanisms: DAG binding to its C1 domain, phosphorylation 
at T133 by PKC δ and ε, and increased expression levels also mediated by PKC 
δ and ε. 
 
 
§ PKC δ, PKC ε and RasGRP3 are novel therapeutic targets for uveal melanoma. 
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Summary 
Constitutive activation of Gαq signaling by mutations in GNAQ or GNA11 occurs in over 
80% of uveal melanomas (UM) and activates the MAP-kinase signaling cascade. 
Protein kinase C (PKC) has been implicated as a link, but the mechanistic details 
remained unclear. We identified PKC δ and PKC ε as required and sufficient to activate 
MAPK in GNAQ mutant melanomas. We find that MAPK activation depends on the 
presence of Ras and is caused by RasGRP3, a Ras exchange factor that is significantly 
and selectively overexpressed in response to GNAQ/11 mutation in UM. RasGRP3 
activation occurs via PKC δ- and ε-dependent phosphorylation as well as PKC-
independent, DAG-mediated membrane recruitment, possibly explaining the limited 
effect of PKC inhibitors to durably suppress MAP-kinase signaling in UM. The findings 
nominate RasGRP3 as a possible therapeutic target for cancers driven by oncogenic 
GNAQ/11. 
 
Significance 
Uveal melanoma (UM) is the most lethal form of melanoma with a 10-year survival rate 
of approximately 50%. Once metastatic, no effective treatment options exist as current 
targeted therapy approaches and immune checkpoint blockade regimens are less 
effective than in cutaneous melanomas. The identification of PKC δ and PKC ε as 
critical effectors downstream of an activated Gαq signaling pathway highlights them as 
specific targets for therapy. The critical role of RasGRP3 as an oncogenic effector and 
transcriptional target downstream of GNAQ/11 may offer additional opportunities for the 
development of treatments.  
 
 
Introduction 
Uveal melanoma (UM) is the most common intraocular malignancy in adults and cannot 
be effectively treated once metastatic (Singh et al., 2005). UM is a genetically and 
biologically distinct type of melanoma with a significantly lower 10-years survival than 
cutaneous melanoma. It originates from melanocytes of the choroidal plexus, ciliary 
body or iris of the eye and does not harbor mutations in BRAF, NRAS and KIT that 
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prevail in cutaneous melanomas arising from intraepithelial melanocytes of the skin or 
mucosa. Instead, UM harbor mutually exclusive mutations in GNAQ, GNA11, PLCB4 or 
CYSLTR2 (Johansson et al., 2016; Moore et al., 2016; Van Raamsdonk et al., 2009; 
Van Raamsdonk et al., 2010). GNAQ and GNA11 encode closely related, large 
GTPases of the Gαq family, which are α subunits of heterotrimeric G proteins that 
operate downstream of G protein–coupled receptors (GPCRs). Relevant Gαq coupled 
receptors in melanocytes include endothelin and WNT receptors, which play a critical 
role in melanocyte differentiation and survival and have been associated with invasion 
and metastasis in melanoma, and the cysteinyl leukotriene receptor 2 (CYSLTR2) 
(Dissanayake et al., 2007; Moore et al., 2016; Sheldahl et al., 1999; Shin et al., 1999). 
Approximately 95% of GNAQ and GNA11 mutations in melanoma affect codons 209 
(Q209) of the G-proteins with only 5% affecting codon 183 (R183) in the Ras-like 
domain. The respective mutations result in complete or partial loss of GTPase activity, 
thereby locking GNAQ/11 into its active protein, GTP-bound confirmation, resulting in a 
dominant acting oncogene that transforms melanocytes (Van Raamsdonk et al., 2009; 
Van Raamsdonk et al., 2010). Similar to the mutations in RAS oncoproteins, the defects 
in GNAQ or GNA11 GTPases are difficult to target directly, making it important to 
delineate the oncogenic effector pathways downstream to identify opportunities for 
targeted therapy. Recently, mutations in the CYSLTR2, a Gq-coupled GPCR, and the 
downstream effector of Gαq PLCB4, encoding a phospholipase Cβ (PLC β) isoform, 
have been reported in the small percentage of UMs without GNAQ or GNA11 
mutations(Johansson et al., 2016; Moore et al., 2016). 
 
MAP-kinase pathway activation has been shown as one contributing factor to GNAQ 
mediated oncogenesis (Van Raamsdonk et al., 2009). However, how exactly mutant 
GNAQ/11 relays signals to the MAPK pathway in UM remains to be clarified. Recent 
studies have demonstrated MAP-kinase pathway activation is at least in part mediated 
by protein kinase C (PKC)(Chen et al., 2014; Wu et al., 2012). PLC β, a direct 
downstream effector of mutant GNAQ/11, hydrolyzes the membrane phospholipid 
phosphatidylinositol 4,5-bisphosphate to release two potent second messengers: 
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). DAG provides a docking site 
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within the inner leaflet of the plasma membrane for enzymes, including specific PKC 
isoforms (Hubbard and Hepler, 2006) and IP3 releases calcium from the smooth 
endoplasmic reticulum (ER). Calcium also activates some PKC isoforms. The PKC 
family consists of at least 10 serine/threonine kinases, which are subdivided into classic, 
novel and atypical isoforms (Griner and Kazanietz, 2007). The classical PKC isoforms 
(α, βI, βII, γ) can be activated by both DAG and calcium, while the novel PKCs (δ, ε, θ, 
η) are only DAG-dependent. By contrast, the atypical PKCs (ζ, ι) are not responsive to 
DAG or calcium. Which specific PKC isoforms mediate the activating effect on the 
MAPK pathway in the context of GNAQ or GNA11 mutations remains unclear. Recent 
studies have also demonstrated that mutant GNAQ/11 promote uveal melanoma 
tumorigenesis by activating YAP independent of PLC β(Feng et al., 2014; Yu et al., 
2014). Furthermore, prior studies have shown that PKC inhibition alone in UM cell lines 
is not sufficient to completely suppress MAPK signaling (Chen et al., 2014), suggesting 
that PKC-independent effectors may be involved that mediate MAPK signaling in 
GNAQ/11 mutant cells. Alternative effectors that may connect PLCβ-generated IP3 and 
DAG to MAPK signaling in UM and have recently been implicated in various types of 
cancer are members of the RasGRP family of RasGEFs (Ras guanine nucleotide 
exchange factors) (Ksionda et al., 2013). Studies in BRAFV600E melanomas suggest that 
therapeutically meaningful responses in patients can only be expected if marked 
suppression of the MAPK pathway is achieved (Bollag et al., 2010; Flaherty et al., 
2012). To achieve this goal in UM, a more refined understanding of the connection 
between MAPK signaling and GNAQ/11 mutant in uveal melanoma is required to 
develop more effective targeting strategies. 
 
Here, we identified PKC δ and PKC ε as key PKC isoforms to activate MAPK signaling 
in GNAQ mutant melanoma and identified RasGRP3 as a critical signaling nodule 
linking oncogenic GNAQ to Ras/Raf/MEK/ERK pathway via multiple mechanisms, 
implicating PKC δ and PKC ε and RasGRP3 as possible therapeutic targets for cancers 
driven by oncogenic GNAQ/11. 
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Results 
PKC δ  and PKC ε  are the critical PKC isoforms that mediate MAP-kinase signaling 
in uveal melanoma cells with GNAQ/11 mutation 
Oncogenic GNAQ activates MAPK in part via PKC (Chen et al., 2014). However, 
which of the numerous isoforms are involved in this signaling is not entirely resolved. 
The significant homology among the different isoforms α, βI, βII, γ, δ, ε, θ, η, ζ, ι poses 
challenges for their specific identification. In order to overcome this limitation we tested 
the specificity of commercially available PKC antibodies by transfecting HA-tagged full 
length PKC isoforms or their catalytic subunits (Figure S1A and S1B) into 293FT cells 
and identified a panel of specific antibodies that was used to screen a panel of 
melanoma cells with or without GNAQ/11 mutations. As shown in Figure 1A, five PKC 
isoforms (PKC α, PKC δ, PKC ε, PKC ζ and PKC ι) were consistently expressed 
throughout all 6 melanoma cells tested (MEL202, 92-1, OMM1.3, MEL270 with GNAQ 
mutations and OMM-GN11, UPMD-1 with GNA11 mutations). These isoforms were also 
expressed at similar levels in most of the melanoma cell lines tested that had mutations 
other than GNAQ or GNA11 and partly originated from cutaneous melanomas (C8161, 
MM415, MM485, SK-MEL-28). This expression pattern is concordant with prior reports 
for melanoma cell lines (Denning, 2012; Oka and Kikkawa, 2005). By contrast, PKC βI, 
PKC θ, PKC η and PKC γ expression was not detected in any of the 13 melanoma cells, 
mostly consistent with previous studies(Denning, 2012; Gilhooly et al., 2001; Oka and 
Kikkawa, 2005; Selzer et al., 2002), although PKC η expression has been described in 
some melanoma cells and tissues (Oka and Kikkawa, 2005). While PKC β II showed 
differential expression between melanoma cell lines with and without GNAQ/11 
mutations, it was not expressed in all GNAQ/11 mutant cell lines, ruling it out as a 
universal effector downstream of mutant GNAQ/11. While PKC ζ and ι, where found to 
be expressed in GNAQ/11 mutant cell lines, they are classified as atypical PKCs as 
they are not activated by either calcium or DAG, making them unlikely candidate 
effectors of mutant Gαq. By contrast, PKC α, δ and ε, which were consistently 
expressed in all uveal melanoma cell lines with GNAQ or GNA11 mutations, are 
candidates to mediate MAPK signaling in GNAQ mutant melanomas. 
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 In order to determine which of these PKC isoforms mediate MAPK signaling in 
GNAQ/11 mutant cells, we performed siRNA mediated knock down of PKC isoforms 
(PKC α, δ, ε as well as  ζ  used as control) alone or in combination in 3 GNAQ mutant 
cell lines (92-1, OMM1.3, and MEL202) and examined MAPK signaling at the level of 
pMEK and pERK. As shown in Figure1B and Figure S1C, knockdown of either PKC δ or 
ε alone resulted in partial inhibition of pMEK and pERK, whereas knockdown of PKC 
α and PKC ζ  had no significant effect. Combined knockdown of PKC δ and ε inhibited 
pMEK and pERK levels similar to knockdown of GNAQ itself. Similar results were 
observed in the GNA11 mutant cell line UPMD-2 (Figure S1C). In contrast to the 
suppressive effect on MAP-kinase pathway activation in GNAQ mutant cell lines, 
knockdown of GNAQ, PKC δ and PKC ε singly or in combination had no effect in three 
melanoma cell lines without GNAQ mutations (C8161 from cutaneous origin, MUM2C 
and MEL285 from uveal origin) (Figures 1C and S1D). By contrast, knockdown of PKC 
βII in 92-1 with GNAQ mutation (Figure 1B) and OMM-GN11 and UPMD-2 cell lines with 
GNA11 mutation (Figure S1E) had no effect on pMEK and pERK. 
To establish an initial connection between specific PKC isoforms and mutant 
GNAQ, we co-transfected PKC isoforms (α, δ, ε, ζ, ι) together with GNAQQ209L into the 
293FT model cell line. As shown in Figure1D, only PKC δ and PKC ε strongly 
synergized with GNAQQ209L in activating the MAP-kinase pathway. We confirmed that 
the synergistic effect was dependent on the kinase activity of PKC δ and ε, by using 
kinase-dead mutants of PKC δ and ε (Figure S2A). Furthermore, only GNAQQ209L but 
not wild type GNAQ synergized with PKC δ and ε, indicating that the synergy depended 
on active GNAQ (Figure S2B).  
PKC is recruited by DAG to the plasma membrane which contributes to its 
activation. In normal melanocytes, both PKC α and PKC δ were localized in the 
cytosolic fraction, while PKC ε were localized in both cytosolic and membrane fractions 
(Figure S2E). After stimulation with the stable DAG analogue TPA, the PKC isoforms α, 
δ, and ε but not ζ translocated to the membrane (Figure S2G). In uveal melanoma cell 
lines with GNAQ/11 mutations, PKC α and PKC ζ were localized in the cytosolic 
fraction, while a considerable portion of the PKC δ and PKC ε signal was localized at the 
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membrane (Figure S2F). These data further support the notion that the main active 
isoforms in the context of GNAQ/11 mutations are PKC δ and PKC ε. 
 
As previously shown, cell proliferation of GNAQ mutant UM cells depends on 
GNAQ and PKC as knockdown of GNAQ or PKC inhibition suppress cell proliferation 
(Chen et al., 2014; Khalili et al., 2012; Wu et al., 2012). To determine whether this 
inhibition is mediated by PKC δ and PKC ε, we investigated their contribution by 
knocking them down both singly and in combination. Combined knockdown of PKC δ 
and PKC ε but not PKC α reduced cell proliferation similar to knockdown of GNAQ in 
GNAQ mutant cell lines (92-1 and OMM1.3), while the knockdown had no effect in cell 
lines without GNAQ mutations (Figure 1E). Similar results were obtained in the GNA11 
mutant cell line (UPMD-2) (Figure 1E). We confirmed that expression levels of the 
targeted genes remained suppressed during the course of these experiments (Figure 
S2C and S2D). Taken together, these experiments indicate that PKC δ and PKC ε are 
essential for MAPK signaling and proliferation of UM cell lines with GNAQ mutations but 
not in related cell lines without GNAQ mutations. 
 
Ras is required for oncogenic GNAQ to activate the MAP-kinase pathway 
 To determine at which level mutant GNAQ activates the MAP-kinase pathway, 
we investigated whether the activation depended on Ras. We found that 293FT cells 
transfected with GNAQQ209L had increased levels of Ras-GTP compared to controls, 
which could be further increased by co-transfection of PKC δ and ε compared to co-
transfection of GFP (Figure 2A), PKC α, or ζ (Figure S2H). TPA also increased Ras-
GTP levels. All three Ras isoforms (Hras, Kras and Nras) were activated by oncogenic 
GNAQ (Figure 2B).  Only simultaneous knockdown of all three Ras isoforms, but not 
knockdown of individual isoforms, decreased pMEK and pERK levels comparable to 
knockdown of GNAQ and inhibited cell proliferation (Figures 2C and S2I) indicating that 
activation of MAPK signaling in GNAQ mutant cells requires the presence of Ras, with 
no specific preference of any specific Ras family member.  
 
The Ras-GEF RasGRP3 is implicated as a signaling module in uveal melanoma  
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To determine how mutant GNAQ activates Ras/MAPK signaling, we compared 
gene expression profiles between five GNAQ or GNA11 mutant melanoma cells 
(GNAQmt: 92-1, MEL202, OMM1.3; GNA11mt: UPMD-1, OMM-GN11) and five GNAQ/11 
wildtype melanoma cells with either NRAS (SK-MEL-2, MM415, MM485) or BRAF 
mutations (SK-MEL-5 and MUM2C). As shown in Figure 3A, RasGRP3, a Ras-guanyl 
nucleotide exchange factor (RasGEF), ranked at the top of 487 differentially expressed 
genes between (cut off: p value <0.05; fold change >2 or <-2). In addition, RasGRP3 
spiked our particular interest because Ras-MAPK activation via RasGRP3 is regulated 
by the 2nd messenger DAG and by phosphorylation by PKC(Ksionda et al., 2013). 
Quantitative reverse transcriptase (RT)-PCR experiments confirmed that RasGRP3 
mRNA is markedly up-regulated (>100 fold) in melanoma cell lines with GNAQ or 
GNA11 mutations, compared to normal melanocytes or melanoma cell lines with other 
mutations. Other RasGRP family members as well as the RasGEF SOS1 did not show 
any increased expression levels in melanoma cell lines with GNAQ or GNA11 mutations 
or showed differential expression differences in these cells (Figure S3A). A comparison 
of RasGRP3 mRNA levels across TCGA datasets (Figure 3C) revealed that RasGRP3 
expression in uveal melanoma tissues is consistently increased and considerably higher 
than in other cancer types, including cancers reported to have elevated RasGRP3 
expression, such as breast cancer (Nagy et al., 2014), prostate cancer (Yang et al., 
2010), lymphoma(Teixeira et al., 2003)  and cutaneous melanoma(Yang et al., 2011). 
Interestingly, the four samples in the 478 samples of cutaneous melanoma samples that 
harbor GNAQ or GNA11 hotspot mutations, also had elevated RasGRP3 mRNA with 
levels comparable to those present in uveal melanoma (Figure 3D). These data suggest 
that higher expression of RasGRP3 is specifically associated with the presence of 
oncogenic GNAQ/11. 
Western blotting with validated antibodies (Figure S3B) demonstrated that the 
increased RasGRP3 mRNA levels lead to elevated protein levels (Figure 3E and Figure 
S3C). Similarly, the lymphoblastoid cell line Ramos B (Teixeira et al., 2003) and the 
cutaneous melanoma cell lines SK-MEL-5 and UACC257 (Yang et al., 2011) have been 
reported to express elevated RasGRP3 levels. We found that both RasGRP3 and p-
RasGRP3(T133) protein levels in melanoma cell lines with GNAQ mutations were 
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significantly higher than in  cell lines without GNAQ mutations, including SK-MEL-5 and 
UACC257 (Figure S3D). We also examined RasGRP3 protein expression in formalin-
fixed, paraffin-embedded (FFPE) uveal melanoma tissues by immunohistochemistry 
(IHC). As shown in Figure S3E, two conjunctival melanoma cell lines that had no 
GNAQ/11 mutations (CRMM1 and CRMM2) had no detectable expression of RasGRP3 
protein by western blot and immunohistochemistry (Figure 3F), while uveal melanoma 
cell lines with GNAQ mutation (92-1, MEL270) or GNA11 mutation (OMM1) showed 
strong RasGRP3 immunoreactivity (Figure 3F and Figure S3F).  RasGRP3 protein 
expression was also detected by immunohistochemistry in uveal melanoma tissues with 
GNAQ and GNA11 mutations (Figure 3G).  
 
Elevated RasGRP3 expression and RasGRP3 phosphorylation is a consequence 
of mutant GNAQ signaling and is mediated by PKC δ and PKC ε 
We next investigated the connections between GNAQ and RasGRP3 and noted 
that knockdown of GNAQ diminished not only p-RasGRP3 levels but also decreased 
total RasGRP3 (Figure 4A). Conversely, expression of GNAQQ209L or GNA11Q209L but 
not BRAFV600E in human melanocytes significantly increased total RasGRP3 and 
pRasGRP3 levels (Figure 4B). The upregulation of RasGRP3 expression depended on 
PKC activity. Treatment of OMM1.3 cells with PKC inhibitor AEB071 (500nM) 
suppressed RasGRP3 levels in a time-dependent manner, starting after 10h, peaking at 
24h after drug administration (Figure 4C). This time course contrasts with the 
suppression of RasGRP3 phosphorylation by AEB071, which was detectable already at 
2h and peaked at 10h. Maximal pERK inhibition was observed at about 24 h, probably 
reflecting the combined effect of inhibition of RasGRP3 phosphorylation and 
downregulation of its expression. Similar results were observed in the 92-1 cell line 
(Figure S4A). The effect of PKC inhibition on RasGRP3 expression levels and p-
RasGRP3 levels was dose dependent in three different GNAQ mutant cell lines 
incubated with two different PKC inhibitors, AEB071 and AHT956 for 24h (Figure 4D 
and Figure S4B), but had no effects on RasGRP3 expression while inhibiting 
pRasGRP3 in melanoma cell lines with BrafV600E or NRAS mutations (Figure S4C), 
which have very weak expression of RasGRP3 compared to GNAQ mutant cells. TPA 
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increased RasGRP3 expression levels and RasGRP3 phosphorylation in a time 
dependent manner in human melanocytes, with no significant effects on RasGRP1 and 
SOS1 (Figure 4E and Figure S4E). TPA also increased RasGRP3 expression in human 
melanoma cells with BRAF mutations (Figure S4D). These data indicate that activation 
of PKC in melanocytic cells results in upregulation of RasGRP3 expression as well as 
T133 phosphorylation of RasGRP3, and that the markedly elevated protein and 
phosphorylation levels found in GNAQ mutant melanoma cells are a consequence of 
Gαq-mediated upregulation of PKC activity. Among the four PKC isoforms PKCα, 
PKCδ, PKCε, PKCζ, which we found to be invariably expressed in GNAQ or GNA11 
mutant UM cell lines, only PKCδ and PKCε robustly phosphorylated T133 of RasGRP3, 
whereas PKC α and PKC ζ had weaker effects with no significant consequences on 
MAPK signaling (Figure 4F and Figure S4F).  Combined knockdown of PKC δ and PKC 
ε suppressed RasGRP3 expression and RasGRP3 phosphorylation and resulted in 
maximal inhibition of pERK and pMEK compared to non-target siRNA control, while 
knockdown of individual PKC isoforms and combined knockdown of PKCα with δ or ε 
had no significant effect (Figure 4G).  
Next we investigated the mechanism of RasGRP3 upregulation. We ruled out a 
positive feedback loop involving MAPK activation and RasGRP3 regulation by 
suppressing MAP-kinase signaling using the two different MEK inhibitors PD0325901 
and Trametinib (Figure 4H and Figure S4G). The YAP1 pathway has been shown to 
play an important role in GNAQ mutant melanoma development(Feng et al., 2014; Yu et 
al., 2014). Knock-down of YAP1 did not affect RasGRP3/MAPK regulation and 
activation (Figure S5A). Combined inhibition of the YAP1 and PKC/MAPK pathways 
also neither synergistically suppressed MAPK signaling nor increase cleaved PARP 
levels, compared to combined inhibition of PKC and MEK (Figure S5B-C). The YAP1 
inhibitor verteporfin or the MET inhibitor INC280 did not increase the effects of the PKC 
inhibitor AEB or the MEK inhibitor 162 (Figure S5F). The oncogene tyrosine kinase 
receptor MET was found to be highly expressed in UM cell lines with GNAQ/11 mutation 
in our microarray experiment (Figure 3A). However, knock-down of MET or inhibition 
with the MET inhibitor INC280 had no effect on RasGRP3 and pRasGRP3 levels nor 
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pERK in UM cell lines (Figure S5D-E). These data indicate that neither the YAP1 
pathway nor MET signaling is involved in the upregulation of RasGRP3. 
Some cancers have RasGRP3 amplifications (Figure S6D), but we found no 
incident of amplification of RasGRP3 or PKC δ and PKC ε in UM cell lines (Figure S6A 
and S6B) and UM tissue samples (Figure S6C). To investigate whether the upregulation 
occurs at the transcription level, we knocked-down GNAQ and found that it decreased 
RasGRP3 mRNA levels in the GNAQ mutated UM cell lines OMM1.3 and 92-1 (Figure 
S6E). By contrast, the knockdown had no effect on the RASGEF SOS1. The PKC 
inhibitors AEB071 and AHT956 also both decreased RasGRP3 mRNA, also with no 
effect on SOS1 mRNAs (Figure S6G). Conversely, overexpression of GNAQQ209L or 
GNA11Q209L in melanocytes increased RasGRP3 mRNA (Figure S6F). Similarly, TPA 
increased RasGRP3 mRNA in both melanocytes and in the BRAF-mutant melanoma 
cell line UACC257 (Figure S6H). All together, these data suggest RasGRP3 regulation 
in the context of GNAQ mutations occurs transcriptionally and involves PKC signaling. 
 
RasGRP3 mediates MAPK activation in GNAQ mutant melanoma cells 
 The consistently elevated expression levels implicated RasGRP3 as a candidate 
protein involved in activation of Ras signaling downstream of mutant GNAQ/11. 
Knockdown of RasGRP3 in GNAQ mutant melanoma cell lines significantly reduced 
levels of pMEK and pERK but not pAKT (Figure 5A and Figure S7A) but had no effect in 
other melanoma cell lines (Figure 5B). Similar results were obtained with individual 
siRNAs instead of siRNA pools (Figure S7B). Knockdown of other RasGRP isoforms 
had no effect on pMEK and pERK (Figure S7C), but the protein levels of RasGRP1, 
RasGRP2 and RasGRP4 were already too low to be detectable even before 
knockdown. Knockdown of SOS1 only slightly reduced pMEK and pERK levels (Figure 
S7D). Knockdown of either GNAQ or RasGRP3 also decreased RasGTP levels in 
GNAQ mutant uveal melanoma cell lines (Figure S7E). 
siRNA mediated knockdown of RasGRP3 also significantly decreased 
proliferation of GNAQ mutant cells during a five day proliferation assay, whereas it had 
no significant effect on other melanoma cell lines (Figure 5C). We verified that 
RasGRP3 expression remained suppressed during the course of the experiment (Figure 
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S7F). Stable shRNA-mediated knockdown of RasGRP3 also markedly reduced tumor 
growth in a mouse xenograft model of the GNAQ mutant cell line 92-1 (Figure 5D-F).  
 To further confirm that RasGRP3 modulates MAPK signaling in the setting of 
GNAQ mutation, we co-transfected 293FT cells with GNAQQ209L combined with 
individual RasGRP isoforms and examined their effects on MAPK signaling. As shown 
in Figure 5G, RasGRP1, RasGRP3 and RasGRP4 alone but not RasGRP2 induced 
pERK , while only co-transfection GNAQQ209L with RasGRP1 or RasGRP3 potentiated 
MAPK signaling as evidenced by markedly increased pMEK and pERK level. In 
contrast, co-transfection GNAQQ209L with RasGRP2 had no synergistic effect on MAPK 
signaling, consistent with the notion that RasGRP2 activates Rap but not Ras (Ksionda 
et al., 2013). We ruled out that these differences were due to variation in the expression 
levels of the transfection constructs using antibodies against the myc tag of RasGRP 
isoforms. GNAQQ209L increased pRasGRP1 (T184) and pRasGRP3(T133) levels in 
RasGRP1- and RasGRP3- expressing cells, respectively, indicating that oncogenic 
GNAQ can in principle activate both RasGRP1 and RasGRP3. Our data indicate that in 
the context of uveal melanoma cells RasGRP3 is the relevant effector and is 
upregulated at the mRNA level, whereas RasGRP1 is not expressed (Figure 3E). 
 
RasGRP3 is activated by PKC phosphorylation and DAG-mediated membrane 
recruitment  
Next we performed a series of experiments to examine the mechanisms by which 
RasGRP3 activates MAPK signaling in uveal melanoma cells. In B cells, it has been 
shown that PKC can phosphorylate RasGRP3 at T133, located in its Ras exchange 
motif (REM) (Zheng et al., 2005).  A phosphorylation site mutant RasGRP3T133A 
substantially reduces but does not abrogate all RasGRP3 activity in B cells (Aiba et al., 
2004). To determine the role of T133 phosphorylation in the context of mutant 
GNAQ/11, we introduced RasGRP3T133A into 293FT cells. RasGRP3 T133A also was less 
effective in synergizing with GNAQQ209L in activating the MAP-kinase pathway (Figure 
6A) and Ras (Figures S7G) than wild type RasGRP3. We confirmed that the PKC 
isoform expression patterns in 293FT cells and UM cells are comparable, with the 
exception of PKC θ, which  is only expressed in 293FT cells (Figure S7H).  These data 
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indicate that PKC phosphorylation at T133 also contributes to RasGRP3 mediated 
Ras/MAPK signaling in the context of mutant GNAQ. However, the phosphorylation site 
mutant of RasGRP3 had a residual activating effect on the MAP-kinase pathway, 
indicating some RasGRP3 activity may be PKC independent.  To resolve this, we 
inhibited PKC activity using the pan-PKC inhibitor AEB071 in 293FT cells transfected 
with combinations of mutant or wild type RasGRP3 with mutant GNAQ (Figure 6B). At a 
concentration of 1µM AEB071 was able to completely abrogate T133 phosphorylation of 
RasGRP3, consistent with prior studies showing complete extinction of PKC activity at 
this concentration(Chen et al., 2014). By contrast, AEB071 had no significant effect on 
MAP-kinase pathway activation of wild type RasGRP3 or RasGRP3T133A in the absence 
of mutant GNAQ, indicating that this residual activity was PKC independent. As a 
control, addition of a MEK inhibitor, PD0325901 in this experiment blocked all MAPK 
activation (Figure 6C). These data indicate that PKC phosphorylation at T133 
contributes to RasGRP3 mediated MAPK signaling, but pinpoints a residual activating 
effect of RasGRP3 that does not rely on phosphorylation at T133 or PKC activity, which 
is consistent with the reported work in B cells (Aiba et al., 2004).  
RasGRP3 is recruited to the inner leaflet of the plasma membrane by binding 
DAG via its C1 domain(Lorenzo et al., 2001). In order to determine the role of 
membrane recruitment of RasGRP3 on MAPK signaling, we generated C1 domain 
deletion constructs of RasGRP3. As shown in Figure 6D, deletion of the C1 domain of 
RasGRP3 significantly reduces the ability of mutant GNAQ to activate the MAP-kinase 
pathway and the RasGRP3 activity could be further reduced by mutating the T133 
phosphorylation site. The effect of C1 deletion could be completely rescued by adding 
Fyn or Src membrane binding motifs(Chen and Resh, 2001) to the RasGRP3 C1 
deletion mutants (Figure 6E), indicating that C1-mediated membrane binding is 
essential for GNAQ-mediated activation of MAP-kinase signaling. All together, these 
data demonstrate that membrane binding via the C1 domain and T133 phosphorylation 
cooperate in RasGRP3-mediated activation of MAPK signaling in the setting of GNAQ 
mutations. 
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Discussion 
Constitutive activation of the MAPK pathway (RAS/RAF/MEK/ERK) is common in 
cutaneous melanoma and typically occurs through mutations and/or amplification of 
signaling modules such as BRAF or NRAS. The MAP-kinase pathway is also activated 
in UM, but mutations of these specific genes are conspicuously absent. Instead, this 
disease appears to be defined by mutations of the Gαq pathway. The mechanism how 
these mutations result in activation of MAP-kinase signaling is incompletely understood. 
Prior studies have shown Gαq mediated activation of MAPK through the kinases Pyk2 
and src-mediated activation of Ras in PC12 cells and HEK293 cells (Della Rocca et al., 
1997; Dikic et al., 1996; Lev et al., 1995), an effect that is PKC independent. Gαq has 
also been shown to activate the MAP-kinase pathway independent of RAS through 
RasGRP2 and Rap1 mediated activation of B-Raf in PC12 cells(Guo et al., 2001). 
Another RAS-independent mechanism of MAP-kinase pathway activation by Gαq 
involving PKC-mediated phosphorylation of Raf-1 has been shown using NIH3T3 cells 
(Kolch et al., 1993), COS-1 cells (Ueda et al., 1996) and COS-7 cells (Schonwasser et 
al., 1998) as models. 
We show that in the context of oncogenic GNAQ signaling found in UM, the 
activation of the MAP-kinase pathway occurs through a different mechanism. We find 
that Ras is required for GNAQ mediated MAPK activation, and identify a signaling 
module that involves PKCδ and ε and RasGRP3, which is required and sufficient to 
activate Ras/MAPK signaling.  
Among the more than 10 different PKC isoforms we found that irrespective of 
GNAQ or GNA11 mutation status, PKC α, δ, ε, ζ were ubiquitously expressed in 
melanoma cells, while PKC ι was only weakly expressed, mostly consistent with 
published reports. Among the consistently expressed isoforms we identified PKC δ and 
PKC ε as the main functionally important isoforms that mediate MAPK signaling in uveal 
melanoma cells. Only knock-down of PKC δ or PKC ε but not other PKC isoforms 
significantly reduced MAPK signaling in GNAQ mutant melanoma cells. Only Combined 
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depletion of PKC δ and PKC ε but not combined knockdown of either PKC ζ with δ or ε 
(Figure 1B-C and Figure S1C-D), or PKC α with δ or ε (Figure 4G) extinguished MAP-
kinase pathway signaling and inhibited proliferation GNAQ mutant melanoma cell lines 
but had no such effect on melanoma cell lines with other mutations (Figure 1E). 
Concordantly, co-transfection GNAQQ209L with PKC δ or PKC ε but not PKC α, PKC ζ, 
and PKC ι potentiated MAPK signaling in 293FT cells (Figure 1D).  
We identified PKC δ and PKC ε as the main effector isoforms downstream of 
oncogenic GNAQ/11 that activate MAPK signaling. The lack of MAPK activation by PKC 
α is of interest as it, like PKC δ and PKC ε, also contains a DAG binding domain. 
However, we found PKC α localized mainly in the cytoplasm in uveal melanoma cell 
lines, while a considerable fraction of PKC δ and PKC ε were localized at the 
membrane, consistent with their activation in this setting.  
RasGRP3 belongs to family with four related RAS GTP exchange factors (GEFs) 
RasGRP1-4, which all contain a REM (Ras exchange motif)-Cdc25 domain that 
mediates Ras activation and a C1 domain that mediates membrane localization by 
binding DAG (Ebinu et al., 1998; Ksionda et al., 2013; Stone, 2011). RasGRP proteins 
display tissue-specific expression patterns: RasGRP1 is primarily expressed in the 
cerebral cortex, cerebellum, T cells and to a lesser extent in B cells; RasGRP2 is 
expressed in striatum and platelets and their precursors; RasGRP3 is highly expressed 
in B cells, macrophages and endothelial cells; whereas RasGRP4 is restricted to mast 
cells, thymocytes and neutrophils. Recent studies have shown that RasGRP3 plays an 
important functional role in the formation and progression of a variety of human cancers 
(Nagy et al., 2014; Yang et al., 2010; Yang et al., 2011).  
We show that the significantly increased expression level of RasGRP3 in UM is a 
direct consequence of Gαq signaling and that Gαq signaling not only increases 
RasGRP3 transcription in a PKC-dependent manner but activates RasGRP3 by two 
independent mechanisms: membrane recruitment and phosphorylation by PKC δ and 
PKC ε.  
RasGRP3 is reported to be expressed at elevated levels in some human cancers 
such as Burkitt’s lymphoma, metastatic prostate cancer, human breast cancer and 
BRAF mutant melanoma(Nagy et al., 2014; Teixeira et al., 2003; Yang et al., 2010; 
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Yang et al., 2011). Here we show that the expression level of RasGRP3 in GNAQ or 
GNA11 mutant melanoma cell lines and human uveal melanoma tissues, by far 
exceeds the expression levels of the previously reported tissue types indicating a 
specific role of this protein in uveal melanoma. Our results indicate that GNAQ signaling 
and PKC δ and ε are involved in upregulating RasGRP3 expression, and that this effect 
is restricted to melanocytes as mutant GNAQ did not increase RasGRP3 expression 
levels in 293FT(data not shown). Other RasGRP family members were not expressed at 
significant levels in UM cell lines. The mechanistic details behind this apparently 
Rasgrp3- and cell type- specific regulation remain to be elucidated.  
Phosphorylation of RasGRP3 at Threonine 133 by PKC enhances RasGRP3’s 
ability to maximally activate Ras signaling in antigen receptor-stimulated B cells, and in 
that context is suggested to be mediated by PKC θ (Aiba et al., 2004)and PKC β(Zheng 
et al., 2005). We confirm the critical role of RasGRP3 phosphorylation at T133 in the 
setting of GNAQ mutations with PKC δ and PKC ε as the relevant PKC isoforms for this 
modification in UM. We show that mutating the PKC phosphorylation site of RasGRP3 
(T133A) partially but not completely attenuated RasGRP3 mediated MAPK signaling. 
The residual RasGRP3 activity depended on its DAG binding domain. These findings 
indicate the existence of two independent mechanisms that activate RasGRP3 in UM, 
one depends on PKC phosphorylation at T133 and the other requires DAG. DAG here 
most likely serves to recruit RasGRP3 to the plasma membrane, as the DAG-binding 
domain could be substituted by either Fyn or Src membrane target motifs. This PKC-
independent activity may explain why PKC inhibition fails to induce sustained 
suppression of MAPK signaling in GNAQ mutant melanomas(Chen et al., 2014). In line 
with our findings, both the catalytic domain and the C1 domain of RasGRP3 are 
required in BCR-mediated Ras activation(Oh-hora et al., 2003). 
Our finding that GNAQ mediates MAPK signaling via PKC δ and PKC ε in UM 
may have important clinical implications and provide an opportunity for refined 
therapeutic targeting. To date, clinical studies on UM utilize pan-PKC inhibitors including 
AEB071, but more specific compounds targeted to the PKC δ and PKC ε hold the 
promise of an improved therapeutic index. The key role of RasGRP3 in mediating 
signals to the MAP-kinase pathway implicates it as a novel therapeutic target. 
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Experimental Procedures 
Plasmids and reagents 
The GNAQ and GNA11 constructs have been previously described (Chen et al., 2014). 
HA-tagged PKC isoforms full-length cDNA constructs (α, βII, δ, ε, γ, η, ζ, ι), HA-tagged 
catalytic domains cDNAs (α, βII, δ, ε) and HA-tagged kinase dead cDNAs (δ, ε) are gifts 
from Bernard Weinstein(Soh and Weinstein, 2003) and purchased from Addgene 
(Cambridge, MA). Myc tagged human RasGRP1, RasGRP2, RasGRP3 and RasGRP4 
cDNAs were cloned into pEF6 vector. RasGRP3-T133A construct was generated by 
site-directed mutagenesis using Quikchange II kit (Agilent Technologies, Santa Clara, 
CA) following the manufacturer’s instruction. C1 domain is deleted to create two C1 
domain deletion mutant constructs (RasGRP3-ΔC1 and RasGRP3-T133A-ΔC1) by 
using overlap extension PCR. PCR products were inserted into pEF6 vector following 
EcoRI and XbaI digestion. RasGRP3- ΔC1 and RasGRP3-T133A- ΔC1 were fused at 
their N-terminus to 20 N-terminal Src or 16 N-terminal Fyn amino acids(Chen and Resh, 
2001) by using PCR method, resulting in generation of Src-RasGRP3- ΔC1, Src-
RasGRP3- T133A-ΔC1, Fyn-RasGRP3- ΔC1, and Fyn-RasGRP3-T133A-ΔC1. The 
primers used for Src fusion constructs are as follows: 5’- 
GGTGGAATTCATGGGGAGTAGCAAGAGCAAGCCTAAGGACCCCAGCCAGCGCCG
GCGCAGCCTGGAGCCAGGATCAAGTGGCCTTGGG-3’ and 5’- 
ATCCTCTAGAGCCATCCTCACCATC -3’. The primers used for Fyn fusion constructs 
are: 5’-
GGTGGAATTCATGGGGAGTAGCAAGAGCAAGCCTAAGGACCCCAGCCAGCGCCG
GCGCAGCCTGGAGCCAGGATCAAGTGGCCTTGGG-3’ and 5’-
ATCCTCTAGAGCCATCCTCACCATC -3’. All constructs were verified by DNA 
sequencing. AEB071 , AHT956 , MEK162 and INC280 were synthesized at Novartis 
Pharma AG (East Hanover, NJ, USA). Human HGF is from Peprotech( Rocky Hill, NJ). 
PD0325901 and Trametinib were obtained from Chemie TEK(Indianapolis, IN). TPA 
and Verteporfin were purchased from Sigma (St Louis, MO) 
 
Cell culture 
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The sources of uveal melanoma cell lines have been previously described(Griewank et 
al., 2012). Cutaneous melanoma cell lines SK-MEL-5, UACC257, MM415, MM485, SK-
MEL-28 were purchased from UCSF cell culture facility. All melanoma cell lines were 
maintained in RPMI 1640 with 10%FBS. Human Burkitt’s lymphoma Ramos cells were 
obtained from ATCC (Manassas, VA) and were maintained in RPMI 1640 with 10%FBS. 
293FT cells were obtained from Invitrogen (Grand Island, NY) and were cultured in 
DMEM with 10%FBS. Immortalized human melanocytes (a gift from Dr. David Fisher, 
Dana Farber Cancer Institute, Boston, MA) and normal human melanocytes from 
Invitrogen were cultured in 254 media supplemented by human melanocyte growth 
supplements (HMGS-2; Invitrogen). Melan-a cells (a gift from Dr Dorothy Bennett, St 
George University, London, UK) were maintained in RPMI with 10% FBS and 200 nM 
TPA TPA . 
 
Transient transfection, lentiviral transduction and siRNA mediated gene 
knockdown 
For transient transfection, 293FT cells were transfected using lipofectamine 
2000(Invitrogen) following the manufacturer’s instruction. Cells were processed 24h-48h 
after transfection. Lentiviral generation and transduction have been described 
previously (Chen et al., 2014). All siRNA pools were obtained from Dharmacon 
(Rockford, IL).  The list of siRNA for different genes is shown in the supplementary 
procedures. 30nM siRNAs for each gene were transfected using lipofectamine 
RNAimax reagent according to manufacturer’s instructions (Invitrogen). For combination 
knock down, non-target siRNAs were used to keep each sample same amount of total 
siRNAs. After 48 to 72h transfection, cells were either lysed or used for cell proliferation 
analysis. 
 
Western blot analysis and cell proliferation 
Cell lysis and immunoblotting were performed as described(Chen et al., 2014). For 
antibody details, see supplementary information. Western blot bands were subjected to 
densitometric analysis using image Studio software from Li-COR Biosciences (Lincoln, 
Nebraska).  For short term proliferation assays (over one week), cells were transfected 
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with indicated siRNAs. After 48h transfection, cells were counted using TC10 automated 
cell counter(Bio-Rad, Hercules, CA) and plated in triplicate into 6-well plates at 5x104 
cells/well and cultured for the indicated times. Cells were collected by trypsinization and 
counted in a TC10 automated cell counter (Bio-Rad, Hercules, CA). For long term 
proliferation assays, cells were plated at 10 cm plates and then treated with or without 
inhibitors. After 12 to 18 days, cells were stained with Crystal Violet. 
 
Assay for activated Ras 
The Ras activation assay was performed using an agarose-bound GST-fused RBD of 
Raf-1 as described by the manufacturer (Millipore). Briefly, 293FT cells were transfected 
with indicated plasmids for 24h and then were washed with cold PBS and lysed. The 
activated Ras was pulled down with agarose-conjugated Raf-1 RBD, followed by 
SDS/PAGE gel electrophoresis and immunoblotting with a pan-Ras antibody or a Ras 
isoform-specific antibody.  
 
Taqman Real time RT-PCR 
RNA was isolated from cells by using RNeasy mini kit (Qiagen, Valencia, CA) according 
to the manufacture’s instruction and reverse-transcribed with random primers 
(Invitrogen) and Moloney murine leukemia virus reverse transcriptase. Real-time PCR 
was performed in duplicate or triplicate using Eppendorf RealPlex2. Gene expression 
was evaluated using SensiMix II probe (Bioline) and specific probes described below. 
Each sample has been normalized to GAPDH and quantified with the comparative CT 
method according to the manufacturer’s instructions. The following combinations of 
primers and probes were used to analyze the expression of human RasGRP1: forward, 
AAGCTCCACCAACTACAGAACT; reverse, AGGGAGATGAGGTCCTTGAGAT; probe, 
FAM-CCACATGAAATCAATAAGGTTCTCGGTGAG-TAMRA and human GAPDH 
forward, GAAGGTGAAGGTCGGAGT; reverse, GAAGATGGTGATGGGATTTC; probe, 
FAM-AGGCTGAGAACGGGAAGCTTGT-TAMRA. SOS1 (Hs00362308_m1), RasGRP2 
(Hs00183378_m1), 3 (Hs00209808_m1) and 4 (Hs01073182_m1) probes and primers 
were obtained at Applied Bio System.  
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Microarray experiments 
Purified RNA was analyzed for quality using chip-based capillary electrophoresis 
(Bioanalyzer, Agilent, Inc) and quantity and purity was determined with a NanoDrop 
spectrometer. The GeneChip WT PLUS Reagent kit was used for amplification, 
fragmentation and biotin-labeling (Affymetrix, Santa Clara, CA).  The labeled cDNA was 
hybridized to Human Transcriptome 2.0 microarrays (Affymetrix, Santa Clara, CA).  The 
signal intensity fluorescent images produced during Affymetrix GeneChip hybridizations 
were read using the Affymetrix Model 3000 Scanner and converted into GeneChip 
probe results files (CEL) using Command and Expression Console software 
(Affymetrix). The array data were normalized at gene level and outliers were identified 
and removed if have by using Affymetrix expression console software. Gene level 
differential expression was compared between 5 GNAQ/11 mutant melanoma cells and 
5 BRAF/Nras mutant melanoma cells by using Affymetrix transcriptome Analysis 
Console (TAC) software. Algorithm option is one-way between-subject Anova 
(Unpaired). Filter criteria:  (1) fold change (linear)<-2 or fold change (linear)>2; (2) 
Anova p-value <0.05. Human Transcriptome Array 2.0 covered more than 285,000 full-
length transcripts including >245,000coding transcripts. Total 67528 genes are coved 
on this array including 44699 coding genes. 
 
Human uveal melanoma cell lines and human uveal melanoma tissues 
Immunohistochemistry 
The 92.1, Omm1 and Mel270 UM cell lines were grown in RPMI (Life Technologies, 
Paisley, UK) plus 10% FCS. The CRMM1 and CRMM2 conjunctival melanoma cell lines 
were grown in Ham's F-12K (Kaighn's) Medium (Life Technologies) plus 10% FCS. At 
~75% confluence the cells were removed from the bottom of a 75cm2 tissue culture 
flask using a cell scraper. The cells were then pelleted at 1500rpm for 2 minutes and 
fixed in 10% neutral buffered formalin for 10 minutes. Following fixation the cells were 
washed in PBS before transferring the cell pellet to a microfuge tube for a final wash 
with PBS and centrifugation at 8000rpm for 1 minute. The supernatant was removed 
and 100µl of 4% molten agar was added and mixed quickly into the cell pellet prior to 
centrifugation at 14,000rpm for 30 seconds. The agar cell pellet was then removed from 
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the microfuge tube and placed into a tissue cassette for processing through a series of 
alcohols and xylenes. After dehydration the pellet was paraffin wax embedded such that 
the agar tip containing cells was at the surface of the block. 
 
Sections (4 µm thick) cut from the cell pellet blocks, human uveal melanoma specimens 
underwent immunohistochemistry as previously described (Lake et al., 2013). In brief, 
antigen retrieval and IHC were performed using the Dako PT Link and Autostainer Plus 
systems and Envision™ FLEX Kit according to standard manufacturers’ procedures 
(Dako UK Ltd, Cambridgeshire, UK). Positive staining was visualized either by use of 3-
amino-9-ethylcarbazole (AEC, Vector Laboratories Ltd., Peterborough, UK, 30 min). 
The slides were counterstained with Mayer’s hematoxylin (VWR, Leicestershire, UK) 
and cover-slipped using an aqueous mountant (Aquatex™, VWR). The following 
RasGRP3 primary antibody was used: rabbit polyclonal, 13162-1-AP (ProteinTech, 
Manchester, UK) at 1:200. Omission of the primary antibody served as the negative 
control for the rabbit polyclonal. Human duodenal tissue served as a positive control. 
 
Mouse xenograft  
The constructs containing shRNA sequence targeting human RasGRP3 or non-target 
shRNAs were obtained from Genecopoeia (Rockville, MD). The RasGRP3 shRNA 
expressing stable 92-1 cell lines were generated following the manufacturer’s 
instructions.  Nude mice (Jackson laboratory) were injected subcutaneously in the 
flanks with 2x106 cells suspended in matrigel. Mice were monitored for 13 weeks after 
injection and then were sacrificed. Tumors were collected and weighted. All animal 
experiments were performed in accordance with a protocol approved by the Institutional 
Animal Care and Use Committee of the University of California, San Francisco. 
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Figure legends 
Figure 1 PKC δ  and PKC ε  are important downstream effectors of oncogenic 
GNAQ in mediating MAPK signaling. A)  Expression of PKC isoforms in melanoma 
cell lines with and without GNAQ or GNA11 mutations.  Previously validated antibodies 
against various PKC isoforms (Fig.S1A and S1B) were tested on a broad panel of 
melanoma cell lines. Suitable positive controls (PC) for isoforms found not to be 
expressed are shown on the right most lane. B) Knockdown of GNAQ and PKC 
isoforms δ and ε reduced levels of pMEK and pERK in the GNAQ mutated uveal 
melanoma cell line 92-1, but not in the GNAQ wild type cell line C8161 (C). Cells were 
transfected with respective siRNAs either singly or in combination and then lysed. 
Abbreviations: -: no siRNA ; NT: non-targeting siRNA. D) PKC δ and PKC ε synergized 
with GNAQQ209L in activating MAPK in 293FT cells. 293FT cells were transfected for 
24h. PKC isoforms expression was detected using HA tags and GNAQQ209L  using a 
Glu-Glu tag (EE). E) Effect of knockdown of PKC α, PKC δ, PKC ε and GNAQ or 
GNA11 on the proliferation of GNAQ mutant melanoma cells (92-1 and OMM1.3) and 
GNA11 mutant cell line (UPMD-2) and GNAQ/11 wild type melanoma cells (C8161 and 
SK-MEL-28 from cutaneous origin and MEL285 from uveal origin). Cells were 
transfected with various combination of siRNAs as indicated. 48h after transfection, 
cells were counted and seeded at equal density. Cells were counted at day 1, 3, 5 after 
plating. Abbreviations: -: no siRNA control . NT: non-targeting siRNA control.  
 
Figure 2 Oncogenic GNAQ activates Ras  A) GNAQQ209L transfected alone or 
combined with PKC δ or PKC ε into 293FT cells increased Ras-GTP levels. 293FT cells 
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were transfected with indicated cDNA plasmids for 24h. Ras-GTP pull-down was 
performed and detected by Western blot with a pan-Ras antibody. TPA stimulation was 
used a positive control. Expression levels of GNAQQ209L were monitored with Glu-Glu 
(EE) tag. PKC δ and PKC ε were detected via HA tags. B) Oncogenic GNAQ activates 
all three Ras isoforms. 293FT cells were transfected with indicated cDNA plasmids for 
24h. Ras-GTP pull-down was performed and detected by Western blot with Ras 
isoform-specific antibodies. C) Depletion of Ras isoforms reduced MAPK signaling as 
evidenced by decreased pMEK and pERK in GNAQ  mutant melanoma cell lines. Three 
human uveal melanoma cell lines with GNAQ mutation (92-1, OMM1.3 and MEL202) 
were transfected with mock (-), non-targeting siRNAs (NT), siRNAs against GNAQ, 
Hras(H), Kras(K), Nras(N) or indicated combinations for 72h and lysed.  
 
Figure 3 RasGRP3 is upregulated in uveal melanoma cells with GNAQ/11 
mutations. A) Scatter plot of top 487 genes (left panel) and heatmap of top 30 
genes(right panel) of differentially expressed genes between 5 GNAQ/11 mutant (mt) 
and 5 GNAQ/11 wild type (wt). B) Quantitative RT-PCR shows markedly elevated 
RasGRP3 mRNA levels in 6 GNAQ mutant cells (92-1, MEL202, OMM1.3, MEL270, 
UPMM2 and UPMM3) and 3 GNA11 mutant cells (OMM-GN11, UPMD-1 and UPMD-2), 
compared to 3 types of human melanocytes (IHM: immortalized human melanocytes; 
NHM: normal human melanocytes) and 7 human melanoma cell lines without GNAQ/11 
mutations. Three (MUM2C, MEL285 and MEL290) melanoma cell lines without 
GNAQ/11 mutations are from uveal origin.  C) RasGRP3 mRNA expression across 
different human cancers from TCGA RNAseq data. RasGRP3 expression is highest in 
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uveal melanoma. D) Cutaneous melanomas with GNAQQ209P or GNA11Q209L mutations 
in the TCGA have increased RasGRP3 mRNA expression, comparable to uveal 
melanomas. E) Western blot shows increased RasGRP3 protein levels in human 
melanoma cells with GNAQ/11 mutations compared to cell lines with other mutations 
(MEL285, MUM2C and MEL290 are of uveal and the other GNAQ/11 wt cell lines are of 
cutaneous origin). RasGRP1, RasGRP2 and RasGRP4 were not detectable in 
melanoma cells with GNAQ/11 mutations. 293FT lysates transfected with RasGRPs 
cDNA were used as positive control. F) RasGRP3 immunohistochemistry in human 
uveal melanoma cell lines. RasGRP3 immunohistochemistry of pellets of formalin-fixed 
paraffin-embedded GNAQ mutant UM cell lines (92-1 and MEL270) and GNAQ/11 wild 
type lines (CRMM1 and CRMM2). G) RasGRP3 immunohistochemistry in 4 uveal 
melanoma tissues with GNAQ mutation and 4 with GNA11 mutations.   
 
Figure 4 Oncogenic GNAQ signaling regulates RasGRP3 expression and 
phosphorylation in uveal melanoma cells. A) Depletion of GNAQ with siRNAs 
decreased RasGRP3 expression and T133 phosphorylation in three GNAQ mutant 
uveal melanoma cells (OMM1.3, 92-1 and MEL202). Cells were transfected with mock 
(-), non-targeting siRNAs (NT), or GNAQ siRNAs for 72 h and lysed. B) GNAQQ209L or 
GNA11Q209L but not wild-type GNAQ, GNA11 or BrafV600E induced increased RasGRP3 
expression and phosphorylation in immortalized human melanocytes. Melanocytes were 
infected with lentivirus expressing indicated proteins for 48h and analyzed by 
immunoblot. Expression levels of GNAQ and GNA11 were monitored using Glu-Glu 
tags. C) The PKC inhibitor AEB071 decreased RasGRP3 expression and 
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phosphorylation in OMM1.3 cells in a time dependent manner. OMM1.3 cells were 
incubated with DMSO or 500nM AEB071 for the times indicated. D) The PKC inhibitors 
AEB071 and AHT956 decreased RasGRP3 expression and phosphorylation in OMM1.3 
cells in a dose dependent manner. OMM1.3 cells were incubated with DMSO or 
AEB071 or AHT956 at indicated doses for 24h. E) TPA increased RasGRP3 expression 
and phosphorylation in human melanocytes. Immortalized human melanocytes were 
incubated with or without 200nM TPA for the indicated times. F) PKC δ and PKC 
ε increase T133 phosphorylation of RasGRP3 in 293FT cells. 293FT cells were 
transfected with indicated cDNAs for 24h. G) Knockdown of PKC δ and PKC ε 
decreased RasGRP3 expression and phosphorylation in GNAQ mutant cells. Western 
blot of 92-1 cells transfected for 72h with mock (-), non-targeting siRNAs (NT), PKC α, 
δ, or ε siRNAs, singly or in indicated combination. H) The MEK inhibitor PD0325901 has 
no effect on RasGRP3 expression and phosphorylation in GNAQ mutant cells. MEL202 
and 92-1 cells were incubated with PD0325901 at different doses for 24h. 
 
Figure 5 RasGRP3 is important for GNAQ-mediated MAP-kinase pathway 
activation and proliferation. A) siRNA mediated knock down of RasGRP3 decreases 
pMEK and pERK levels in three GNAQ mutant melanoma cells (92-1, omm1.3 and 
mel270)  but not in three GNAQ/11 wild type melanoma cells (B). MUM2C is from uveal 
origin. Cells were transfected with mock(-), non-targeting or RasGRP3 siRNAs for 72h 
and lysed for Western blot analysis. C) RasGRP3 knockdown reduces proliferation of 
melanoma cells with GNAQ mutations (92-1, MEL270 and OMM1.3) but not of cell lines 
with other mutations (SK-MEL-5 and UACC257). Cells were transfected with non-
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targeting or RasGRP3 siRNAs. 48h after transfection, cells were counted and plated at 
equal density. Cells were counted at day 1, 3, 5 after plating.  D) Western blot of stable 
knockdown of RasGRP3 using shRNA. 92-1 cells were infected with lentivirus 
expressing two different shRNAs for RasGRP3 and selected with puromycin. NT: non-
targeting shRNA. E) shRNA-mediated knockdown of RasGRP3 in 92-1 cells (from panel 
D) decreased the number and size of colonies. Cells were stained with crystal violet 
after 18 days of culture. F) Nude mice were injected subcutaneously with 2x106 92-1 
cells expressing RasGRP3 shRNA-1(n=5) or non-targeting shRNA (n=5).  Tumors sizes 
and weights for both experimental arms 13 weeks after injection. . G)  The effect of co- 
transfection of GNAQQ209L with 4 different RasGRP isoforms on MAPK signaling. 293FT 
cells were transfected with mock (-), GFP, GNAQQ209L, RasGRP1, RasGRP2, RasGRP3 
or RasGRP4 plasmids either singly or in combination as indicated. After 24h, cells were 
lysed and blotted. Arrows indicate that pRasGRP1 antibodies recognized both 
RasGRP1 T184 phosphorylation and RasGRP3 T133 phosphorylation.  
 
Figure 6 Both PKC mediated phosphorylation and C1 domain are required for 
RasGRP3-mediated MAPK activation. A) Mutating the PKC phosphorylation site of 
RasGRP3 (T133A) partially attenuated RasGRP3 mediated MAPK signaling in 293FT 
cells. 293FT cells were transfected with mock(-), GFP, GNAQQ209L, RasGRP3 
wt(GRP3wt), RasGRP3T133A(GRP3T133A) either singly or in indicated combination. After 
24h, cells were lysed and subjected to Western blot. RasGRP3 wild type and mutant 
expression were detected with Myc tag antibody. GLU-GLU tag (EE) was used to detect 
GNAQQ209L. The top panel shows a schematic diagram of the RasGRP3 T133A 
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construct. B) PKC inhibition fails to completely abrogate RasGRP3-mediated MAPK 
signaling. 293FT cells were transfected with GFP, GNAQQ209L, RasGRP3 wt, or 
RasGRP3T133A either singly or in indicated combinations. After 24 h, transfected cells 
were treated with 1µM AEB071 (AEB) or vehicle for another 24h and then lysed. C) The 
MEK inhibitor PD0325901(PD) completely suppressed RasGRP3-mediated MAPK 
signaling. 293 FT cells were co-transfected with GNAQQ209L and RasGRP3 T133A or with 
GNAQQ209L and RasGRP3wt. After 24h, cells were treated for another 24h with DMSO, 
1µM AEB071(AEB), 1µm AHT956 (AHT), 100nM PD0325901(PD), 1µM AEB+100nM 
PD or 1µM AHT956+100nM PD, respectively. D) Both T133 phosphorylation and C1 
domain of RasGRP3 contribute to oncogenic GNAQ-mediated MAPK signaling. 293 FT 
cells were transfected with indicated constructs for 24h and lysed. Left panel shows that 
schematic diagram of the RasGRP3 C1 domain deletion constructs used. E) 
Restoration of MAPK activation by expression of membrane-targeted forms of 
RasGRP3 in 293FT cells. RasGRP3 constructs tagged with the membrane targeting 
motifs of Fyn and Src protein as shown in left panel.  293FT cells transfected with 
indicated RasGRP3 mutant constructs for 24h.  
 
Fig.7 Model of oncogenic GNAQ activates MAPK signaling in uveal melanoma. 
GTP-bound GNAQ directly activates PLC β, which generates the second messenger 
DAG. DAG activates PKC δ and PKC ε by binding their C1 domains. The Ras activator 
RasGRP3 represents a critical signaling node linking oncogenic GNAQ to the 
RAS/RAF/MEK/ERK signaling pathway by three independent mechanisms: binding of 
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membrane recruitment by DAG, phosphorylation and upregulation of expression by 
PKC δ and PKC ε. 
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Extended Experimental Procedures  
 
Western blotting antibodies  
PKC isoform antibodies used as follows: PKC α(#2056), PKC δ(#2058), PKC 
ζ(#9368) and PKC ι (#2998) from Cell Signaling Technology; PKC θ (#610090) 
and PKC ε (#610085) from BD Biosciences; PKC γ (#133800) from Invitrogen; 
PKC η (#H00005583-B02) from Abnova; PKC βI(sc-209), PKC βII(sc-210), and 
PKC δ (sc-937) from Santa Cruz; PKC βII(#1514-1) was from Epitomics. 
 
pMEK(#9121), pERK(#4370), SOS1 (#12409), PARP (9542), cleaved 
PARP(9541), YAP1 (14074), MET( 3127), p-MET(3077), Myc tag( 2276S) and 
RasGRP3(#3334) were from Cell signaling technology; GNAQ(E-17), ERK2(c-
14), Nras(F155), Kras(sc-30), Hras(sc-520) and Braf(C-19) were from Santa 
Cruz; β-actin (#A1978) was from Sigma; Glu-Glu(MMS-115P) and HA(MMS-
101P)  from Covance Inc. (Princeton, NJ, USA); P-p90RSK (#2006-1), RasGRP2 
(#S2451) from Epitomics(Burlingame, CA); Human RasGRP1 (JR-E160) was 
generated by the Roose lab together with Epitomics; RasGRP4 (ab96293) and p-
RasGRP3(T133)(ab124823) from Abcam. P-RasGRP1(T184) was generated by 
the Roose lab through immunization with the peptide SRKL-pT-QRIKSNTC 
together with Eurogentech/AnaSpec (Fremont, CA).  
 
Quantitative RT-PCR 
Total RNA was extracted using PureLink  RNA Mini kit (Thermo Fisher Scientific, 
Waltham, MA). For quantitative RT-PCR, mRNA was retrotranscribed using 
SuperScript III First-Strand Synthesis Super Mix (Thermo Fisher Scientific ). 
Real-time PCR was performed using standards and Power SYBR Green PCR 
Master Mix (Thermo Fisher Scientic) with Bio-rad C1000 Touch Thermal Cycler 
Samples were normalized to a ribosomal protein SB34 with standard 
comparative CT methods. Primer sequences are shown below: RasGRP3 
forward-CTCTGCATGTATCGAAATGCCA; RasGRP3 reverse- 
CTACTTCCCGAAATTCCTCAGTC; SOS1 forward- 
GTAGGATGAACTTGCCCCTG; SOS1 reverse-GCTGCCCTACGAGTTTTTCA.  
 
Genome-wide SNP Genotyping 
UM cell line DNAs  were genotyped with the illumina Human Omni1-Quad V1.0 
beadchip (Illumina, San Diego) according to the manufacture’s instructions. The 
beadchips were processed and imaged on an illumine Bead Array Reader. Bead 
intensity data obtained for each sample were loaded into Nexus Copy Number 
software from BioDiscovery (EI Segundo, CA) for gene copy number analysis. 
 
Cell fractionation 
Subcellular fractionation was performed using the Subcellular Protein 
Fractionation Kit of Thermo Scientific (Waltham, MA, USA) following the 
manufacture’s instructions. Fractions from cytosolic, membrane and nuclear 
parts were subjected to western blotting with the indicated antibodies. 
 
Statistical Analysis 
Statistical significance was assessed using a standard 2-tailed t test using prism 
6.0 software (GraphPad software). P<0.05 was considered statistically 
significant. 
 
 
 
 
 
 
 
 
 
 
 
siRNAs 
All siRNAs below were purchased from Dharmacon:  
 
 
 
GENE siRNA description Catalog number 
GNAQ On-TARGETplus  human 
SMARTpool siRNAs 
L-008562-00-0005 
PKC δ On-TARGETplus  human 
SMARTpool siRNAs 
L-003524-00-0005 
PKC ε On-TARGETplus  human 
SMARTpool siRNAs 
L-004653-00-0005 
PKC ζ On-TARGETplus  human 
SMARTpool siRNAs 
L-003526-00-0005 
RasGRP1 On-TARGETplus  human 
SMARTpool siRNAs 
L-008928-00-0005 
RasGRP2 On-TARGETplus  human 
SMARTpool siRNAs 
L-009365-00-0005 
RasGRP3 On-TARGETplus  human 
SMARTpool siRNAs 
L-008517-00-0005 
RasGRP3 On-TARGETplus  human 
RasGRP3 individual 
siRNA-1 
J-008517-07-0002 
RasGRP3 On-TARGETplus  human 
RasGRP3 individual 
siRNA-2 
J-008517-08-0002 
SOS1 On-TARGETplus  human 
SMARTpool siRNAs 
L-005194-00-0005 
HRAS On-TARGETplus  human 
SMARTpool siRNAs 
L-004142-00-0005 
KRAS On-TARGETplus  human 
SMARTpool siRNAs 
L-005069-00-0005 
NRAS On-TARGETplus  human 
SMARTpool siRNAs 
L-003919-00-0005 
Non targeting control On-TARGETplus non-
targeting siRNA pool 
D-001810-10-05 
MET On-TARGETplus  human 
SMARTpool siRNAs 
L-003156-00-0005 
YAP1 On-TARGETplus non-
targeting siRNA pool 
L-012200-00-0005 
PKC α On-TARGETplus  human 
SMARTpool siRNAs 
L-003523-00-0005 
 
 
Supplemental Figure Legends 
 
Figure S1.  PKC isoforms expression in Uveal melanoma.  
A) Validation of specific classical and novel PKC isoform  antibodies. 
293FT cells were transfected with different HA-tagged PKC wt or constitutively 
active PKC isoforms cDNAs. After 24h, cell lysates were subjected to Western 
blotting probed with different PKC isoform antibodies (top panel) and HA 
antibody (lower panel).  
B) Validation of specific atypical PKC isoform  antibodies. 293FT cells were 
transfected with different HA-tagged PKC isoforms full-length cDNAs. After 24h, 
cell lysates were subjected to Western blotting probed with indicated antibodies. 
C and D) The effect of knockdown of GNAQ and PKC isoforms on MAPK 
signaling of levels of pMEK and pERK in two uveal melanoma cell lines with 
GNAQ mutations (OMM1.3 and mel202), one UM cell line with GNA11 mutation 
(UPMD-2) and two GNAQ/11 wild type cell lines (mum2c and mel285 from uveal 
origin)(D). Cells were transfected with respective siRNAs either singly or in 
combination and then lysed. 
E)The effect of siRNA mediated knockdown of PKC βII  on pERK levels  in two 
UM cell lines with GNA11 mutation. As noted, PKC βII is knocked down well in 
OMM-GN11 cells but undetectable in UPMD-2 cells. -: no siRNA. NT: non-
targeting siRNA.  
 
Figure S2  PKC δ  and PKC ε  are important downstream effectors of 
oncogenic GNAQ in mediating MAPK signaling.  
A) kinase dead mutants of PKC δ and ε significantly impaired to activate MAPK with 
oncogenic GNAQ. 293FT cells were transfected with indicated plasmids for 24h 
and analyzed for indicated protein expression with immunoblot. pMEK, pERK 
and p-p90RSK as MAPK signaling readout. PKC isoforms expression was 
detected with HA tag. GNAQQ209L was detected with Glu-Glu tag. δkd and εkd 
mean kinase dead mutant of PKC δ and PKC ε, respectively. A representative 
western blot  was shown in left panel. Quantification of three independent 
western blots for pMEK, pERK and pp90RSK were shown in right panel. Data 
normalized to cells expressing GFP. Value represents mean± s.e.m of the three 
independent experiments.   
B)Oncogenic GNAQ not wild type GNAQ synergistically activate MAPK with wild type 
PKC δ and PKC  ε. 293FT cells were transfected with indicated plasmids for 24h 
and analyzed for indicated protein expression with immunoblot. 
C)	knock down of pkc isoform α after 7 day siRNA transfection. UM	Cells with GNAQ 
or GNA11 mutation were transfected with indicated siRNAs as indicated. After 7 
days, cell were lysed and subjected to western blotting. 
D) knock down of pkc isoforms after 7 day siRNA transfection.	Melanoma	Cell lines 
with GNAQ wt  were transfected with indicated siRNAs as indicated. After 7 days, 
cell were lysed and subjected to western blotting. 
E) Western blots of subcellular fractions of two different normal human 
melanocytes (NHM-1 and NHM-2) probed with indicated antibodies. Notes: PKC 
α and PKC δ are localized in cytoplasmic fractions. C: Cytoplasmic; M: 
Membrane; N:Nucleus.  
F) Western blots of subcellular fractions of 5 UM cell lines with GNAQ/11 
mutations probed with indicated antibodies. As noted, PKC α is localized in 
cytoplasmic fractions, while PKC δ is localized in both cytoplasmic and 
membrane fractions.  
G) Western blots of subcellular fractions of TPA starved mouse melanocytes 
(Melan-a) treated with or without 200 nM TPA for indicated times. As noted, TPA 
induced the membrane translocation for PKC α, δ, ε but not ζ. 
H) GNAQQ209L combined with PKC δ increased more Ras-GTP levels than with 
PKC α and PKC z. in 293FT cells.  293FT cells were transfected with indicated 
cDNA plasmids for 24h. Ras-GTP pull-down was performed and detected by 
Western blot with a pan-Ras antibody. Expression levels of GNAQQ209L were 
monitored with Glu-Glu (EE) tag. PKC δ ,PKC α and PKC ζ were detected via HA 
tags. 
I) Knock down of Ras inhibited the proliferation of UM cell line Omm1.3 . 
Omm1.3 cells were transfected with non-targeting (NT) or all three Ras isoform 
siRNAs. 48h after transfection, cell were counted and plated at equal density. 
Cells were counted at day 1, 3, 5 after plating. 
 
 
Figure S3 RasGRP3	is	markedly	upregulated	in	both	GNAQ	and	GNA11	mutant	
melanoma	cells.		
A) Quantitative RT-PCR shows no expression difference in RasGEFs 
(RasGRP1, RasGRP2, RasGRP4 and SOS1) between human GNAQ/11 mutant 
UM cell lines and GNAQ/11 wt cell lines. 
B)	Validation	of	specific	RasGRP	isoform	antibodies.		293FT cells were transfected 
with GFP, GNAQQ209L and myc tagged RasGRP isoforms cDNAs . 24h later, cells were 
lysed and subjected to western blotting probed with different RasGRP isoform antibodies. 	
C)	western	blotting	of	GNAQ	and	GNA11	mutant	melanoma	cell	lysates	and		
human	melanocyte	lysates	.	IHM: immortalized human melanocytes. NHM-1 and 
NHM-2 : normalized human melanocytes 
D) Both RasGRP3 protein  and phosphorylation  levels are much higher in 
GNAQ mutant melanoma cells (92-1, omm1.3, mel270 and mel202) compared to 
Braf mutant melanoma cells (A375, SK-MEL-5, UACC257 and MALME-3M all 
from cutaneous melanoma) and Ramos cells. 
E) No detectable expression of RasGRP3 in CRMM1 and CRMM2 conjunctival 
melanoma cell lines without GNAQ/11 mutations compared to GNAQ/11 mutant 
UM cell lines (OMM1, 92-1, mel270, mm2.5 and omm2.3) with western blotting. 
F) Positive RasGRP3 IHC staining in OMM1 UM cell lines with GNA11 mutation. 
Images were taken at magnifications 20X. 
 
 
Figure S4 PKC signaling regulates RasGRP3 expression and 
phosphorylation in uveal melanoma cells.  
A) PKC inhibitor AEB071 decreased RasGRP3 expression and phosphorylation 
in 92-1 cells in a time dependent manner. Omm1.3 cells were incubated with 
DMSO or 500nM AEB071 for the times indicated. 
B) Both PKC inhibitor AEB071 (top panel) and AHT956(bottom panel) decreased 
RasGRP3 expression and phosphorylation in 92-1 and mel202 cells in a dose 
dependent manner. 92-1 and mel202 cells were incubated with DMSO or 
AEB071 or AHT956 at indicated doses for 24h. 
C) PKC inhibitor AEB071 has no effect on RasGRP3 expression in SK-MEL-5 
with Braf mutation and MM485 with Nras mutation melanoma cells. SK-MEL-5 
and MM485 were incubated with AEB071 at different dosage for 24 h. 
D) TPA increased RasGRP3 expression and phosphorylation in human 
melanoma cells with Braf mutation. SK-MEL-5 and UACC257 cells were 
incubated with or without 200nM TPA for 72h.  
E) TPA increased RasGRP3 expression in human melanocytes. Immortalized 
human melanocytes were incubated with or without 200nM TPA for the indicated 
times. Quantification of three independent western blots for RasGRP3 and SOS1 
were shown. Data are normalized to cells without TPA treatment. Value 
represents mean± sem of the three independent experiments.  As noted, 2h and 
6h TPA treatment increased SOS1 levels but not statistically significant. 
F) PKC δ and PKC ε increase T133 phosphorylation of RasGRP3 in 293FT cells. 
293FT cells were transfected with indicated cDNAs for 24h.  Quantification of two 
independent western blots for p-RasGRP3 was shown. The p-RasGRP3 level in 
RasGRP3 cDNA transfection alone is normalized to total RasGRP3 level and  
regarded as 1.  
G) The MEK inhibitor Trametinib has no effect on RasGRP3 expression and 
phosphorylation in GNAQ mutant cells. 92-1 and Omm1.3 cells were incubated 
with Trametinib at different doses for 24h. 
 
Figure S5 both YAP and MET pathways do not contribute to RasGRP3 
upregulation and MPAK signaling in UM cells with GNAQ mutations. 
A)siRNA mediated knockdown of Yap1 has no effect on RasGRP3 expression 
and pERK levels in both 92-1 and Omm1.3 cells. Cells were transfected with no 
siRNAs(-), non-targeting siRNAs (NT) and YAP1 siRNAs for 72 hrs and lysed for 
western blotting.  
B) YAP1 inhibitor Verteporfin did not inhibit MAPK signaling in 92-1 UM cells. 92-
1 cells were treated with DMSO, AEB071(250nM), Verteporfin (0.1ug/ml), 
Verteporfin (0.5ug/ml), AEB071(250nM)+Verteporfin(0.1ug/ml) and AEB071 
(250nM)+Verteporfin(0.5ug/ml) for 24h and lysed, probed with indicated 
antibodies. AEB: AEB071. Vert: Verteporfin. CI-PARP: cleaved PARP. 
C) Combined inhibition of YAP1 and PKC/MAPK pathway has no synergy to 
inhibit MAPK pathway and induce apotosis  in 92-1 cells. 92-1 cells transfected 
with non targeting siRNA (NT) or YAP1 siRNA were treated with DMSO, AEB071 
(250nM), MEK162 (50nM) or AEB071+MEK162 for 24h.  
D) MET knockdown did not affect both RasGRP3 and p-RasGRP3 levels in two 
UM cells with GNAQ mutations. 92-1 and Mel270 cells were transfected with no 
siRNA(-), non-targeting siRNAs (NT) or MET siRNAs for 72 hrs and subjected to 
western blotting. 
E) MET inhibitor has no effect on both RasGRP3 and p-RasGRP3 levels on UM 
cells with GNAQ mutations. 92-1 and Omm1.3 cells were treated with DMSO or  
250 nM INC280 in the presence or absence of 10ng/ml HGF for 24h. As noted, 
INC280 inhibited pMET in the presence or absence of the MET ligand HGF. 
F) Combined inhibition of PKC/MAPK and Yap pathway or PKC/MAPK and MET 
pathway has no synergy in inhibiting proliferation of UM cell lines. Omm1.3 and 
92-1 cells were treated with DMSO, AEB071 (250 nM), INC280(250nM) and 
MEK162 (50nM) singly or in combination for 14 days. Cells were stained with 
Crystal Violet. 
 
Figure.S6 RasGRP3 is regulated transcriptionally in GNAQ mutant UM cells.  
A and B) No gene amplification for RasGRP3, PKC ε and PKC δ in 92-1 (A) and 
mel202 (B) UM cells. Extracted cell DNAs are subjected to SNP genotyping. The 
gene copy number was analyzed with nexus copy number software. The copy 
number change and Loss of heterozygosity for the whole genome (left panel) or 
indicated genes (right panel) are shown.  
C) No RasGRP3, PKC δ and PKC ε amplification in human uveal melanoma 
tissues. The data are derived from uveal melanoma TCGA project and 
www.cBioportal.org. 
D) RasGRP3 gene alteration across cancers. The data are from TCGA projects 
and the plot is from cBioportal for Cancer Genomics 
(http://www.cbioportal.org/index.do) 
E) Knock down of GNAQ decreased RasGRP3 mRNA but not SOS1 in both 
omm1.3 and 92-1 cells. Cells were transfected with non-targeting siRNAs (NT) or 
GNAQ siRNA for 72 h and lysed for RNA extraction and quantitative RT-PCR. 
Data are mean ± sem of two to three independent experiments. 
F) Overexpression of GNAQQ209L and GNA11Q209L in human melanocytes 
increased RasGRP3 mRNA levels.  Human melanocytes were infected with 
lentivirus expressing GFP, GNAQQ209L or  GNA11Q209L. After selection with 
blasticidin, RNAs were extracted for RasGRP3 quantitative RT-PCR. Data are 
mean ± sem of two independent experiments. 
G) PKC inhibitor decreased RasGRP3 mRNA significantly in both 92-1 and 
Omm1.3 cells. Cells were treated with 1uM AEB071 or 1uM AHT956 for 24h. 
RNAs were extracted for quantitative RT-PCR.  Data are mean ± sem of two 
independent experiments. 
H)TPA increased RasGRP3 mRNA in both human melanocytes and UACC257 
melanoma cell lines with BRAF mutation. Cells were treated with 200nM TPA for 
48h. Value represent mean ± sem of two independent experiments. 
 
Figure S7 RasGRP3 is functionally important for uveal melanoma cells 
harboring GNAQ mutations  
A) Quantification of three independent western blot experiments as shown in 
Fig.5A. pMEK, pERK and pAKT levels were normalized to total MEK, ERK2 and 
AKT respectively. 
B) RasGRP3 knock down significantly diminished MAPK signaling in UM cells 
with GNAQ mutation. 92-1 and omm1.3 cells were transfected with two different 
individual RasGRP3 siRNAs as well as no siRNA(-) and non-target siRNA (NT) 
controls for 72h. 
C) Only RasGRP3 knock down but not other RasGRP isoform knock down 
diminishes MAPK signaling in omm1.3 cells. Omm1.3 cells were transfected with 
indicated siRNAs for 72h and lysed for western blotting. 
D) Only RasGRP3 but not SOS1 knock down significantly decreased MAPK 
signaling in 92-1 cells. 92-1 cells were transfected with indicated siRNAs for 72h 
and lysed for western blotting. 
E) Knock down of GNAQ and RasGRP3 decreased Ras-GTP levels in omm1.3 
cells. Omm1.3 cells were transfected with non-targeting siRNAs(NT) , GNAQ and 
RasGRP3 siRNAs for 72h and lysed for western blot. 
F) knock down of pkc isoforms after 7 day siRNA transfection. SK-MEL-5 and 
UACC257 melanoma cells were transfected with non target (NT) siRNAs and 
RasGRP3 siRNAs. After 7 days, cell were lysed and subjected to western 
blotting. 
G) RasGRP3 synergizes with GNAQQ209L in activating Ras in 293FT cells. 293FT 
cells were transfected with indicated plasmids for 24h. Activated Ras was 
detected. GNAQQ209L was probed with EE-tag. Myc tag was used to detect 
RasGRP3 or RasGRP3T133A expression. 
H) PKC isoforms expression in 293FT cells compared to UM cell line UPMD-1. 
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